Wall Street Journal. Europe 2004 Anna Wilde Mathews - Abstracts
| Wall Street Journal. Europe 2004 Anna Wilde Mathews | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Celebrex drama may finally prompt changes at the FDA.(United States Food and Drug Administration)(Pfizer Inc.) | Business, international | Anna Wilde Mathews, Barbara Martinez | |||
| FDA wll seek to revise Labels for antidepressants.(Federal Drug Administration) | Business, international | Anna Wilde Mathews | |||
| Second opinion: as drug safety concerns grow, looking overseas for solutions.(safety of prescription drugs) | Business, international | Anna Wilde Mathews | |||
| U.S. is setting a path for biotech generics: regulator plots a course for approving copycats of bioengineered medicines. | Business, international | David P. Hamilton, Anna Wilde Mathews | |||
| Vioxx recall raises questions on FDA's safety monitoring. | Business, international | Anna Wilde Mathews | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.